CU24591B1 - Kit para la restauración del daño cerebral que comprende el factor de crecimiento epidérmico y el hexapéptido secretagogo de la hormona de crecimiento - Google Patents
Kit para la restauración del daño cerebral que comprende el factor de crecimiento epidérmico y el hexapéptido secretagogo de la hormona de crecimientoInfo
- Publication number
- CU24591B1 CU24591B1 CU2018000092A CU20180092A CU24591B1 CU 24591 B1 CU24591 B1 CU 24591B1 CU 2018000092 A CU2018000092 A CU 2018000092A CU 20180092 A CU20180092 A CU 20180092A CU 24591 B1 CU24591 B1 CU 24591B1
- Authority
- CU
- Cuba
- Prior art keywords
- kit
- brain damage
- hormone secretagogue
- hexapepptide
- growth factor
- Prior art date
Links
- 230000006931 brain damage Effects 0.000 title abstract 3
- 231100000874 brain damage Toxicity 0.000 title abstract 3
- 208000029028 brain injury Diseases 0.000 title abstract 3
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 title abstract 3
- 101710111255 Appetite-regulating hormone Proteins 0.000 title abstract 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 title abstract 2
- 101800003838 Epidermal growth factor Proteins 0.000 title abstract 2
- 229940116977 epidermal growth factor Drugs 0.000 title abstract 2
- 102100033367 Appetite-regulating hormone Human genes 0.000 title 1
- 239000003324 growth hormone secretagogue Substances 0.000 title 1
- WZHKXNSOCOQYQX-FUAFALNISA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 WZHKXNSOCOQYQX-FUAFALNISA-N 0.000 abstract 2
- 108010015153 growth hormone releasing hexapeptide Proteins 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 239000008121 dextrose Substances 0.000 abstract 1
- 230000007246 mechanism Effects 0.000 abstract 1
- 210000002569 neuron Anatomy 0.000 abstract 1
- 230000004031 neuronal differentiation Effects 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 239000011780 sodium chloride Substances 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
<p>Kit para la restauración del daño cerebral que comprende el factor de crecimiento epidérmico (EGF) y el péptido secretagogo de la hormona de crecimiento GHRP6, mediante la estimulación de mecanismos de diferenciación y especialización neuronal en células indiferenciadas residentes en el sistema nervioso central o en células neuronales. Las concentraciones en dicho kit son entre 5 µg y 70 µg de EGF por cada mL de dextrosa y entre 0.5 mg y 6 mg de GHRP6 por cada mL de solución salina. La eficacia terapéutica de la combinación farmacéutica es independiente de que la intervención farmacológica ocurra en las primeras horas del daño cerebral, lo que amplía la ventana terapéutica.</p>
Priority Applications (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU2018000092A CU24591B1 (es) | 2018-08-21 | 2018-08-21 | Kit para la restauración del daño cerebral que comprende el factor de crecimiento epidérmico y el hexapéptido secretagogo de la hormona de crecimiento |
| MX2021002063A MX2021002063A (es) | 2018-08-21 | 2019-08-16 | Combinacion farmaceutica que contiene el factor de crecimiento epidermico y el peptido secretagogo ghrp6 para la restauracion del da?o cerebral. |
| CN201980069096.8A CN112912092B (zh) | 2018-08-21 | 2019-08-16 | 用于恢复脑损伤的包含表皮生长因子和促分泌肽ghrp6的药学组合 |
| BR112021003028-0A BR112021003028A2 (pt) | 2018-08-21 | 2019-08-16 | combinação farmacêutica compreendendo fator de crescimento epidérmico e peptídeo de secretagogo ghrp6 para a reparação de danos cerebrais |
| CA3110169A CA3110169A1 (en) | 2018-08-21 | 2019-08-16 | Pharmaceutical combination comprising epidermal growth factor and secretagogue peptide ghrp6 for the restoration of brain damage |
| PCT/CU2019/050006 WO2020038498A1 (es) | 2018-08-21 | 2019-08-16 | Combinación farmacéutica que contiene el factor de crecimiento epidérmico y el peptido secretagogo ghrp6 para la restauración del daño cerebral |
| EP19797979.2A EP3842057A1 (en) | 2018-08-21 | 2019-08-16 | Pharmaceutical combination comprising epidermal growth factor and secretagogue peptide ghrp6 for the restoration of brain damage |
| US17/269,788 US20210196793A1 (en) | 2018-08-21 | 2019-08-16 | Pharmaceutical Combination Comprising Epidermal Growth Factor and Secretagogue Peptide GHRP6 for the Restoration of Brain Damage |
| JP2021509876A JP7299304B2 (ja) | 2018-08-21 | 2019-08-16 | 脳損傷を回復させるための上皮成長因子と分泌促進物質ペプチドｇｈｒｐ６とを含む薬学的組合せ |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU2018000092A CU24591B1 (es) | 2018-08-21 | 2018-08-21 | Kit para la restauración del daño cerebral que comprende el factor de crecimiento epidérmico y el hexapéptido secretagogo de la hormona de crecimiento |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20180092A7 CU20180092A7 (es) | 2020-04-02 |
| CU24591B1 true CU24591B1 (es) | 2022-04-07 |
Family
ID=68461694
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2018000092A CU24591B1 (es) | 2018-08-21 | 2018-08-21 | Kit para la restauración del daño cerebral que comprende el factor de crecimiento epidérmico y el hexapéptido secretagogo de la hormona de crecimiento |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20210196793A1 (es) |
| EP (1) | EP3842057A1 (es) |
| JP (1) | JP7299304B2 (es) |
| CN (1) | CN112912092B (es) |
| BR (1) | BR112021003028A2 (es) |
| CA (1) | CA3110169A1 (es) |
| CU (1) | CU24591B1 (es) |
| MX (1) | MX2021002063A (es) |
| WO (1) | WO2020038498A1 (es) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU23157A1 (es) | 2001-01-03 | 2006-07-18 | Ct Ingenieria Genetica Biotech | COMPOSICION FARMACéUTICA PARA EL TRATAMIENTO DEL DANO TISULAR DEBIDO A FALTA DE IRRIGACION SANGUINEA ARTERIAL |
| CU23529A1 (es) * | 2005-03-02 | 2010-06-17 | Ct Ingenieria Genetica Biotech | Combinación de egf/ghrp-6 para la neuroregeneración del sistema nervioso central posterior al dano autoinmune |
-
2018
- 2018-08-21 CU CU2018000092A patent/CU24591B1/es unknown
-
2019
- 2019-08-16 BR BR112021003028-0A patent/BR112021003028A2/pt unknown
- 2019-08-16 EP EP19797979.2A patent/EP3842057A1/en active Pending
- 2019-08-16 WO PCT/CU2019/050006 patent/WO2020038498A1/es not_active Ceased
- 2019-08-16 US US17/269,788 patent/US20210196793A1/en not_active Abandoned
- 2019-08-16 CA CA3110169A patent/CA3110169A1/en active Pending
- 2019-08-16 MX MX2021002063A patent/MX2021002063A/es unknown
- 2019-08-16 JP JP2021509876A patent/JP7299304B2/ja active Active
- 2019-08-16 CN CN201980069096.8A patent/CN112912092B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021003028A2 (pt) | 2021-05-11 |
| WO2020038498A1 (es) | 2020-02-27 |
| CN112912092B (zh) | 2024-05-24 |
| CA3110169A1 (en) | 2020-02-27 |
| EP3842057A1 (en) | 2021-06-30 |
| JP7299304B2 (ja) | 2023-06-27 |
| CN112912092A (zh) | 2021-06-04 |
| US20210196793A1 (en) | 2021-07-01 |
| MX2021002063A (es) | 2021-04-28 |
| CU20180092A7 (es) | 2020-04-02 |
| JP2021534200A (ja) | 2021-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Solana‐Balaguer et al. | Neuron‐derived extracellular vesicles contain synaptic proteins, promote spine formation, activate TrkB‐mediated signalling and preserve neuronal complexity | |
| CL2017002028A1 (es) | Mejora del suministro de partículas virales al cuerpo estriado y al córtex. | |
| Tighilet et al. | Adult neurogenesis promotes balance recovery after vestibular loss | |
| CO2019012151A2 (es) | Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso | |
| CL2017002481A1 (es) | Terapia de combinación del receptor del factor de crecimiento de fibroblastos (fgfr)/muerte progamada 1 (pd 1) para el tratamiento del cáncer | |
| BR112019005351A2 (pt) | terapia combinada com agonistas de cnp de liberação controlada | |
| MXPA05008487A (es) | Acidos nucleicos expresados en forma diferencial en la barrera hemato-encefalica bajo condiciones de inflamacion. | |
| AU2017227844A1 (en) | Methods for controlled proliferation of stem cells / generating inner ear hair cells using GSK-3-alpha inhibitors | |
| CL2020000855A1 (es) | Anticuerpos monoclonales anti-trkb y métodos de uso. | |
| MX2019006048A (es) | Unidad de tejido nervioso y utilizacion de una unidad de este tipo para la implantacion en el sistema nervioso de un mamifero. | |
| Jerónimo-Santos et al. | Impact of in vivo chronic blockade of adenosine A2A receptors on the BDNF-mediated facilitation of LTP | |
| BR112018067946A2 (pt) | formulações tópicas contendo ciclosporina e usos das mesmas | |
| AR097997A1 (es) | Composición farmaceutica de ibuprofeno y tramadol para uso oftálmico | |
| CO2020013690A2 (es) | Composiciones y métodos para el tratamiento de la distrofia macular | |
| CL2025001818A1 (es) | Uso de aflibercept para tratar o prevenir degeneración macular neovascular relacionada con la edad. | |
| Belecky-Adams et al. | Reactive Muller glia as potential retinal progenitors | |
| CL2015002627A1 (es) | Composiciones para el uso en el tratamiento de trastornos oculares que usan dipiridamol | |
| MX2017015147A (es) | Angiogenesis usando celulas madre de placenta estimuladas. | |
| MX2021002017A (es) | Uso de roluperidona para tratar sintomas y trastornos negativos, aumentar la neuroplasticidad y promover la neuroproteccion. | |
| MX2022004212A (es) | Moduladores de atf6 y usos de los mismos. | |
| CL2025003984A1 (es) | Semaglutida en terapia médica. | |
| DOP2019000269A (es) | Inhibidores de la proteasa del virus del zika y métodos de uso de los mismos | |
| CU20180092A7 (es) | Combinación farmacéutica que contiene el factor de crecimiento epidérmico (fce) y el péptido secretagogo ghrp6 para la restauración del daño cerebral | |
| AR110947A1 (es) | Tratamiento de degeneración de la retina mediante el uso de células progenitoras | |
| SG11201810188VA (en) | Amelioration and treatment of perinatal brain damage with pluripotent stem cells |